1. Scrip
  2. >>Business
  3. >>Deals

Sobi To Go Private In $8.1bn Buyout That Appreciates Growth Strategy

Swedish Firm’s Board, Biggest Shareholder Support Deal

 
• By Mandy Jackson

Agnafit Bidco, comprised of Advent International and an affiliate of GIC Pte Ltd, will pay a premium for the rare disease specialist in an effort to capture value from Sobi’s planned growth.  

Swedish Krona banknotes
Sobi accepted a bid of SEK235 per share; the deal could be derailed if a competing bidder offers SEK251 or more • Source: Alamy

Hemophilia and rare disease specialist Swedish Orphan Biovitrum AB (Sobi) has garnered support from its board of directors and two major investors to take the company private in an $8.1bn buyout that will enable the company to aggressively pursue its growth strategy without pressure from public company investors as it navigates commercial product pressures and potential drug development challenges.

The Sobi board unanimously recommended on 2 September that shareholders accept a SEK69.4bn ($8.1bn) buyout offer from Agnafit Bidco AB,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Aurobindo Expects Lannett Acquisition To Pass FTC Scrutiny; Q1 US Revenue Falls

 
• By Vibha Ravi

Aurobindo is confident its planned Lannett acquisition will pass US FTC scrutiny after an attempt to acquire Sandoz assets was called off in 2020 post a delay in approval. The deal could widen Aurobindo’s US manufacturing presence at a time when its US Q1 revenue saw a year-on-year decline

Analysts Not Impressed With Adaptimmune’s Survival Attempts

 
• By Kevin Grogan

The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.

Bristol Myers Shifts Five Drugs To Bain-Partnered Immunology Venture

 
• By Manas Mishra

Bristol Myers and Bain will form a new company focused on five immunology drugs that Cantor Fitzgerald analysts say have been off investors’ radar.

Private Equity Targets Bavarian Nordic But Major Investor Balks

 
• By Manas Mishra

After “intense negotiations”, Bavarian Nordic’s board plans to recommend a DKK19bn ($2.98bn) offer by private equity firms Nordic Capital and Permira to take the company private.

More from Business